The identification of novel tumor-associated genes represents an important area of cancer research. To that end, we have discovered a number of genes whose expression is altered in breast tumors. One of these genes has been identified as the ring finger protein 11 (RNF11) and its expression is elevated in breast and prostate cancer. The RNF11 gene encodes a 154 amino-acid protein that contains a ring finger and a PY motif. RNF11 is capable of binding numerous proteins, which encompass a wide variety of cellular pathways and mechanisms. This gives RNF11 a corresponding breadth of functions, including involvement in TGF-b and epidermal growth factor receptor (EGFR) signaling. In addition, RNF11 has the potential to mediate the ubiquitination and subsequent proteolysis of many cellular proteins. Thus, it may represent an important target of novel cancer therapies. Oncogene (2004 Oncogene ( ) 23, 2089 Oncogene ( -2095 Oncogene ( . doi:10.1038 Keywords: RNF11; ubiquitination; Smurf2; TGF-b; breast cancer; signaling; EGFR
Ubiquitin-mediated degradation and cancer
In recent years, ubiquitin-mediated protein degradation has been identified as a major regulator of the stability or abundance of numerous proteins. Ubiquitinmediated degradation is a complex process that is comprised of numerous well-defined steps (Joazeiro and Weissman, 2000; Weissman, 2001; Nalepa and Harper, 2003) . Initially, ubiquitin is activated by an ubiquitin-activating enzyme (E1) and is subsequently transferred to an ubiquitin-conjugating enzyme (E2). Ubiquitin is then transferred to its target protein either by an E2 or by an ubiquitin ligase (E3). This process cycles repeatedly and the resultant polyubiquitin chains target the protein to the proteasome for degradation. E3 ligases are classified as HECT-, RING-or U box-type (Joazeiro and Weissman, 2000; Weissman, 2001; Hatakeyama and Nakayama, 2003) . HECT-type E3 ligases (Smurf2, Nedd4, AIP4 and NEDL2) contain WW domains, which bind to PY motifs in other protein partners (i.e. Smad2, Smad3, p73). HECT-type ligases are themselves ubiquitinated by E2s, and subsequently transfer this ubiquitin to the target protein. RING-type E3 ligases are subdivided into those that are capable of causing ubiquitylation on their own (Mdm2, Cbl) or those that act as part of a multisubunit E3 complex (ROC1, APC11). The relatively novel U-box proteins (Aravind and Koonin, 2000; Hatakeyama et al., 2001 ) function similar to RING-type E3s, but mediate some atypical polyubiquitin linkages (Hatakeyama and Nakayama, 2003) . The specificity of these E3 ligases has been discussed elsewhere (Fang et al., 2000) and the importance of these proteins in the regulation of proper cellular function is well established.
It is becoming more apparent that ubiquitin-mediated proteolysis is responsible for the regulation of the levels of a wide variety of cellular proteins. The deregulation of ubiquitin-mediated proteolysis can be detrimental to cellular homeostasis. The resultant loss of protein function can lead to cellular imbalances and tumor development (Sakamoto, 2002) . Thus, this process is becoming a very important force driving cancer research (Gillessen et al., 2002) . Although some losses of protein function in tumors can be attributed to genetic deletion or mutation, loss of some proteins (i.e. p27 KIP1 ) can only be accounted for by accelerated ubiquitin-mediated proteolysis (Slingerland and Pagano, 2000) . In fact, there is an association between the expression of components of the ubiquitin proteolysis pathway and cancer progression. Increased levels of E3 ligases have been observed in numerous different tumor types. The F-box protein Skp2, which is responsible for the degradation of the cdk inhibitor p27 KIP1 , is important in breast and other cancers (Gstaiger et al, 2001; BenIzhak et al., 2003; Shigemasa et al., 2003) . It is well established that loss of p27 KIP1 is associated with poor survival of cancer patients (Catzavelos et al., 1997) . Therefore, the overexpression of Skp2 is a deleterious adaptation/alteration in cancer cells. Other examples of the deregulation of E3 activity in cancers have also been reported. For example, the overexpression of the HECT-type ligase Smurf2, which degrades multiple components of the TGF-b signaling pathway, has been reported in esophageal squamous cell carcinoma and is associated with poor patient prognosis (Fukuchi et al., 2002) . In addition, Mdm2, the E3 responsible for the degradation of p53, is overexpressed in 5-10% of all cancers (Michael and Oren, 2002; Fang et al., 2003) . Thus, it is becoming increasingly apparent that E3 ubiquitin ligases represent potential targets for novel cancer therapies (Momand et al., 1998; Pray et al., 2002) .
The TGF-b signaling pathway TGF-b is secreted from cells into the extracellular matrix where it can bind to TGF-b receptors on the plasma membrane of neighboring cells (Liu et al., 2001; Medrano, 2003) . TGF-b is a member of the TGF-b superfamily of proteins including TGF-b, bone morphogenetic protein (BMP) and activin. The TGF-b signaling pathway is complex and involves positive regulators (R-Smads and co-Smads) and negative regulators (I-Smads and Smurfs). Binding of TGF-b to the TGF-b receptors (TbRI and TbRII) causes a transphosphorylation and activation of the TbRI by TbRII. This leads to the phosphorylation of the receptor-activated Smads (R-Smads) including Smads 2 and 3, which subsequently bind to Smad4. This complex is transported to the nucleus where it induces transcription of TGF-b responsive genes (Mehra and Wrana, 2002) . One of the mechanisms of regulating TGF-b signaling involves Smad7 and Smurf2 (Kavsak et al., 2001; Nakao et al., 1997) . Smad7 binds to Smurf2 (Kavsak et al., 2001 ) and this complex is responsible for the degradation of TbRI, TbRII and the R-Smads, thereby silencing TGF-b signaling (Hayashi et al., 1997; Kavsak et al., 2001) . One important consequence of the activation of the TGF-b pathway is a G1 cell cycle arrest. In many cancers, tumor cells lose the responsiveness to TGF-b, leading to the idea that the disruption of this pathway may be an important factor in the development of cancer (Massague et al., 2000 , Miyazono et al., 2003 . In support of this, many pancreatic and colon cancers demonstrate Smad4 deletions (Miyaki et al., 1999) . In addition, deletions of the TbRII have been reported in colon cancers (Kretzschmar, 2000) . However, this only represents a small fraction of the cancers that are insensitive to TGFb. Thus, there must be other factors that contribute to TGF-b in cancer. These likely include accelerated degradation of the Smads or interference of Smad interactions, both of which would lead to a blunted response to TGF-b (Xu and Attisano, 2000) . Increased expression of Smad7 has been reported in pancreatic carcinomas and inflammatory bowel disease (Monteleone et al., 2001) . Thus, the inhibitory activity of Smad7 and Smurf2 appear to be important in disease states. There may be other as yet unidentified proteins that contribute to the deregulation of the TGF-b signaling pathway and the accompanying TGF-b insensitivity evident in cancer cells.
Ring finger protein 11 (RNF11) in the ubiquitin pathway
Identification of novel proteins involved in the ubiquitin pathway that are overexpressed in cancers may lead to a better understanding of disease progression and potentially give rise to new targets for drug therapy. To that end, we have identified multiple genes from a cDNA library enriched for tumor mRNAs that are elevated in breast cancer (Burger et al., 1998) . One of these clones was identified as RNF11, a 154 amino-acid protein that contains a ring finger in between amino acids 98-140 (Seki et al., 1999;  Figure 1 ). Other important regions are the N-terminal PY motif and a 14-3-3 binding motif located within the ring domain. We have shown that RNF11 is capable of binding numerous proteins, including those involved in the TGF-b and ubiquitin pathways Li and Seth, 2003; Subramanium et al., 2003) . We have also reported that RNF11 is highly overexpressed in breast and pancreatic cancers, and moderately overexpressed in head and neck, colon and lung cancers (Subramanium et al., 2003) . However, the mechanisms behind this overexpression and the resultant consequences remain unclear.
Most of our observations of RNF11 suggest a role in ubiquitin-mediated proteolysis via its interaction with HECT-type E3 ligases Subramanium et al., 2003) . Interestingly, RNF11 is also capable of binding to Cul1, a core member of the SCF (Skp1/Cul1/ F-box protein) complex (Subramanuim and Seth, unpublished observations). This gives RNF11 a potentially important role in protein degradation by HECTand SCF-type E3 ligases. RNF11 may function in a manner similar to the ring finger protein ROC1 in SCFmediated ubiquitination (Joazeiro and Weissman, 2000) . However, whether it be in HECT-or SCF-mediated degradation pathways, RNF11 appears to be important for giving specificity to proteolytic mechanisms (Figure 2 ). We also observe binding of RNF11 to the E2s UbcH5 a, b and c (Subramanium et al., 2003) . This is the first evidence of a protein binding to both E2 and E3 molecules. When bound to UbcH5, RNF11 facilitates the ubiquitination of Smurf2 and of itself (Subramanium et al., 2003) . Thus, it appears that UbcH5 may be the E2 responsible for promoting the RNF11-mediated ubiquitination of Smurf2. The full ramifications of RNF11 interaction with both E2 and E3 proteins need further investigation. This review will focus mainly on the involvement of RNF11 in ubiquitin- 
RNF11 in TGF-b signaling
Through its PY motif, RNF11 can bind to Smurf2, thus making it a potential regulator of TGF-b signaling. RNF11 may also compete with Smad7 binding to Smurf2, thereby disrupting the Smurf2/Smad7 complex (Hayashi et al., 1997; Kavsak et al., 2001 ; Figure 3 ). This would prevent the negative effects of Smurf2 and Smad7 on TGF-b signaling and act to restore TGF-b sensitivity to cells that have lost TGF-b responsiveness. In fact, when RNF11 is overexpressed in 293T cells there is an elevation in TGF-b responsiveness, demonstrating the relevance of RNF11 in TGF-b signaling (Subramanium et al., 2003) . Since breast cancers seem most susceptible to becoming TGF-b resistant (Donovan and Slingerland, 2000; Kretzschmar, 2000) , the overexpression of RNF11 in these cancers may illustrate that the cell is trying to reestablish TGF-b signaling. There are many cancers and cell lines that are resistant to TGF-b, thus it appears that this strategy may not be entirely effective. Why is this so? The answer may lie partly within the RNF11 protein sequence. Near the carboxy terminus, there is a potential AKT phosphorylation site (T135). This site lies within a consensus 14-3-3 binding site (Figure 1 ). This motif is identical to one found in the HECT-type E3 ligase Nedd4 (Jolliffe et al., 2000) , and Nedd4 function has been shown to be regulated by AKT kinase activity (Boehmer et al., 2003) . It is known that phosphorylation of a protein within its 14-3-3 binding site can promote interaction with 14-3-3 (i.e. BAD phosphorylation by AKT; Datta et al., 1999 ). An AKT-mediated sequestration of RNF11 away from Smurf2 by 14-3-3 may prevent RNF11 competition with Smad7 and result in the loss of sensitivity to TGF-b (Figure 3 ). In malignant cell lines that are TGF-b resistant, inhibiting AKT returns TGF-b responsiveness to these cells (Liang et al., 2002; Shin et al., 2002; Viglietto et al., 2002) . This shows the importance of AKT in regulating TGF-b sensitivity, and this may also be important in the regulation of RNF11 function. We have observed multiple RNF11 phosphopeptide fragments by 2-dimensional phosphopeptide analysis, which suggests that other phosphorylation events are also involved in mediating RNF11 function (Connor and Seth, unpublished) .
By using yeast two-hybrid analyses, we have reported that RNF11 binds to numerous proteins involved in signaling, transcription and protein degradation . RNF11 may have other effects on TGF-b/ BMP signaling through its interactions with the AMSH (associated molecule with the SH3 domain of STAM) protein (Tanaka et al., 1999) . AMSH has been shown to induce BMP-mediated transcription by binding to Smad6 (Itoh et al., 2001) . In a similar fashion, AMSH interacts with Smad7 in the TGF-b pathway. TGF-b stimulation enhances AMSH/Smad7 interactions, thereby preventing the degradation of the TGFbR by the Smad7/Smurf2 complex. This is similar to the effect of overexpression of RNF11 on the TGF-b pathway, where RNF11 enhances the activation of TGF-b responsive promoters (Subramanium et al., 2003) , possibly by stabilizing the TbR complex by competing with Smad7 for binding to Smurf2, effectively disrupting and inactivating the Smad7/Smurf2 complex (Figure 3) . It is interesting that while RNF11 and AMSH each act to prevent Smad7 from binding to Smurf2, RNF11 is also capable of causing the degradation of AMSH when complexed with Smurf2 .
RNF11 in the EGFR pathway
The EGFR is a tyrosine kinase, which initiates cell growth and proliferation. Improper regulation of the Role of RNF11 in ubiquitin-mediated proteolysis MK Connor and A Seth EGFR pathway can play an important role in cancer development. Like many extracellular signaling receptors, negative feedback mechanisms allow for the appropriate silencing of EGFR signaling following ligand-dependent receptor activation. One mechanism of EGFR regulation involves clathrin-mediated internalization of the EGFR (Confalonieri et al., 2000) . Upon activation, the EGFR phosphorylates EPS-15 at tyrosine 305. In an elaborate series of events, a multiprotein complex that includes hepatocyte growth factorregulated tyrosine kinase substrate (Hrs) and signaltransduction adaptor molecule (STAM) binds to the EGFR causing its internalization and degradation via lysosomal proteolysis (Asao et al., 1997; Bache et al., 2003) . This process requires an activated EGFR and keeps EGFR signaling in check. EGFR internalization may be inhibited by AMSH. AMSH binds to STAM and could prevent the formation of the complex necessary for EGFR internalization, which would prolong EGFR activation and promote cellular proliferation ( Figure 4) . We have shown that RNF11 binds to AMSH and in the presence of the HECT-type E3 ligase Smurf2 promotes the ubiquitination and degradation of the AMSH protein . Thus, by removing the potential negative effects exerted on EGFR internalization by AMSH, RNF11 can act to restore proper EGFR regulation thereby maintaining/ restoring cellular homeostasis. In addition, it has been shown that RNF11 can bind directly to EPS-15. In order for EPS-15 to form a complex with Hrs and STAM, it must be monoubiquitinated following phosphorylation by the EGFR. Thus, it may be that via its interaction with E2 and E3 ligases RNF11 may mediate the monoubiquitination of EPS-15. This means that RNF11 could promote the internalization and degradation of the EGFR via two distinct proteinprotein interactions (Figure 4) . By sequestering AMSH away from STAM and/or mediating the monoubiquitination of EPS-15, RNF11 may be an important target in cases where increased EGFR signaling is responsible for accelerated cell proliferation and tumor progression.
Other potential functions of RNF11
The interactions of RNF11 with both Smurf2 and AMSH have been recently described and some of the consequences of these interactions have been elucidated Li and Seth, 2003; Subramanium et al., 2003) . However, RNF11 binds with numerous other cellular proteins . As of yet, the net results of these interactions remain unexplained. Some of the more conceptual functions of RNF11 are outlined below.
The protein-tyrosine kinase Syk plays an essential role in lymphocyte development and activation of immune cells (Mustelin and Tasken, 2003) . Syk contains two Src homology 2 (SH2) domains in tandem and multiple autophosphorylation sites. Syk is activated upon binding of tandem SH2 domains to immunoreceptor tyrosine-based activating motif (ITAM) and Syk is critical for tyrosine phosphorylation of multiple proteins that regulate important pathways leading from the receptor, such as Ca (2 þ ) mobilization and mitogenactivated protein kinase (MAPK) cascades. Syk degradation is an ubiquitin-depenent process. In B cells, Syk binds to latent membrane protein 2A (LMP2A) via its SH2 domains in a phosphorylation-dependent manner (Mori et al., 2003) . LMP2A then acts as a scaffold bringing Syk into a complex with the Nedd4 family HECT-type E3 ligase AIP4 (Winberg et al., 2000) . The PY motif in LMP2A binds to the WW domain in AIP4, and recruits Syk for ubiquitination and its subsequent degradation by the 26S proteasome. However, Syk expression is not exclusive to B cells (Yanagi et al., 2001) . It is known that Syk functions as a tumor suppressor in that it can inhibit breast cancer cell growth and metastasis (Coopman et al., 2000) . We have demonstrated that RNF11 is capable of binding to AIP4 via its PY motif . Thus, it is possible that in epithelial cells RNF11 can mirror the function of LMP2A by bringing Syk and AIP4 together. It has been shown that in B cells Syk can activate PI-3 kinase-dependent activation of Akt. Akt activation has been implicated as an important factor in TGF-bresistant mammary epithelial cells. This may implicate Syk in TGF-b resistance in breast cancer. If AIP4 and RNF11 couple to mediate Syk degradation, overexpression of RNF11 would play a role in promoting breast cancer progression (Subramanium et al., 2003) . In addition to the potential role in Syk degradation, it is plausible that AIP4 can target other RNF11 binding partners Li and Seth, 2003) , leading to their ubiquitin-mediated degradation.
One of the most widely reported genetic mutations in cancer is the breast and ovarian cancer susceptibility gene 1 (BRCA1). BRCA1 is a transcriptional regulator that is involved in the DNA damage/repair pathway (Gilmore et al., 2003; Moynahan, 2002; Rosen et al., 2003) . The protein ZBRK1 acts as a repressor of gene transcription, which is dependent on BRCA1 (Peng et al., 2002; Zheng et al., 2000) . ZBRK1 is a 60 kDa KRAB-containing protein with eight central zinc fingers. RNF11 has been shown to interact with ZBRK1 , suggesting a potential role for RNF11 in the BRCA1 pathway. RNF11 may serve to enhance the BRCA1 response by accentuating BRCA1/ ZBRK1 interaction. It has been recently reported that ubiquitination of the HIV TAT protein enhances its transcriptional activity (Bre´s et al., 2003) . This may also be the case for ZBRK1. In contrast, RNF11 may have a negative effect on BRCA1 function by binding to ZBRK1, preventing its interaction with BRCA1. Alternatively, RNF11 may target ZBRK1 for destruction via ubiquitin-mediated proteolysis.
Discussion
We originally identified RNF11 as a protein whose gene product was elevated in breast tumors . The RNF11 gene encodes a 154 amino-acid protein containing a ring finger and a PY motif. Our lab is focused on investigating the cellular function(s) of RNF11, and attempting to unravel the relevance of RNF11 overexpression in cancer. We have determined numerous RNF11 binding partners using yeast twohybrid screening and sequence analysis, the nature of which suggests a number of complex and potentially important functions. These range from signaling to transcriptional regulation and suggest a central role for RNF11 in ubiquitin-mediated proteolysis Li and Seth, 2003; Subramanium et al., 2003) . The two main regions within RNF11 are the PY motif (Figure 1 ), which interacts with WW domains of the Smurf2 and AIP4 HECT-type E3 ligases, and the ring finger domain, which is also an important region in mediating protein-protein interactions including with E2s ( Figure 2 ; Subramanium et al., 2003) . The PY motif is identical to that found in Smad7. Both RNF11 and Smad7 appear to compete for binding to the HECT-type E3 ligase Smurf2 through this PY region. We have yet to determine whether Smurf2 preferentially binds to RNF11 or Smad7, but it is clear that the stoichiometric balance between these three proteins is important. This competition for Smurf2 can have important effects on cell function. When complexed with Smad7, Smurf2 acts to degrade the TGF-b receptor. This would lead to a misregulation of the TGF-b signaling pathway, the likely result being insensitivity to TGF-b, a characteristic of many breast cancer cells. If RNF11 can displace Smad7 from this complex, there would be a stabilization of the TGF-b receptor and a restoration of proper TGFb signaling (Figure 3 ; Subramanium et al., 2003) . Another interesting observation is that in the presence of overexpressed RNF11 and Smurf2, increasing the expression of Smad7 enhances the ubiqtuitylation and degradation of both RNF11 and Smurf2 (Subramanium and Seth, unpublished observations) . However, it appears that the regulation of RNF11 function is more complex. Within its C-terminal region, RNF11 contains a potential AKT site that is located within a 14-3-3 binding motif. This domain may be important in regulating RNF11 function. The 14-3-3 family of proteins are known to be 'molecular anvils', binding to target proteins and rigidly altering their conformation, and this binding depends upon the phosphorylation status of residues within the target protein binding site. RNF11 may therefore have separate and distinct functions depending upon the relationship between one or more AKT kinases and 14-3-3 proteins such that in one conformation RNF11 prevents TGF-b responsive growth arrest, and in another conformation it preserves TGF-b signaling by displacement of Smad7. Thus, the prevention of RNF11 phosphorylation by AKT within the 14-3-3 binding domain may be important for restoring TGF-b sensitivity in resistant cells.
We have identified numerous other binding partners for RNF11. One of these is the AMSH protein and the functional significance of this binding is potentially relevant to more than one signaling pathway. RNF11 can promote the ubiquitination and degradation of AMSH. AMSH can bind and sequester Smad6 and Smad7 from Smurf2 and thus act to maintain the integrity of the BMP and TGF-b signaling pathways, respectively. Accelerated degradation of AMSH could therefore result in the deregulation of these signaling pathways, which could have detrimental effects on cellular function including uncontrolled proliferation and malignant transformation. The stoichiometry of these proteins is likely critical in determining the net results on cellular function and may explain why so many breast cancers express elevated RNF11 protein levels (Subramanium et al., 2003) .
AMSH also may play roles in EGFR signaling. AMSH binds to STAM and may prevent the formation of the complex necessary for EGFR degradation, which would prolong EGFR signaling and promote cellular proliferation (Figure 4) . Interestingly, RNF11 may play a dual role in helping to maintain proper EGFR regulation. By inducing AMSH degradation, proper EGFR internalization may be restored. Also, EPS15 is a binding partner of RNF11, giving RNF11 a potential for involvement in EPS15 monoubiquitination. This is essential for EGFR internalization and degradation. Furthermore, RNF11 has two potential EGFR kinase sites. Thus, phosphorylation of RNF11 by the EGFR may be part of the negative feedback mechanism responsible for controlling EGFR activity.
ZBRK1 is another protein that binds to RNF11. ZBRK1 also binds to BRCA1 and acts to suppress gene transcription in response to DNA damage. The fact that RNF11 is overexpressed in breast cancer and BRCA1 is an important breast cancer gene may not be a coincidence. The relevance of the relationship between RNF11, ZBRK1 and BRCA1 remains to be established, but represents a potentially important avenue of RNF11 function.
We are just beginning to scratch the surface of the involvement of RNF11 in the ubiquitin proteolytic pathway. Via its PY motif RNF11 can bind to at least three HECT-type E3 ubiquitin ligases Li and Seth, 2003; Subramanium et al., 2003) . This gives RNF11 the potential responsibility for mediating the degradation of a wide variety of cellular proteins. Additional observations give an indication of the complexity of the role of RNF11 in ubiquitin-mediated proteolysis. RNF11 binds to the E2 enzymes UbcH5 a, b and c, in addition to the HECT-type E3 ligases. This dual binding to E2 and E3 proteins suggests that RNF11 may be involved in bringing these proteins together for target ubiquitination, and this possibility remains an interesting focus of future investigations. Similar to ROC1, we see RNF11 binding to Cul1, a member of the SCF complex. Thus, it appears that the involvement of RNF11 in ubiquitin-mediated proteolysis is widespread. Determination of the precise conditions that regulate RNF11 interactions with various E2 and E3 proteins will provide valuable insight into the importance of RNF11 as a mediator of cellular protein turnover.
The significance of RNF11 overexpression in tumor cells provides a very complex puzzle. In some cases, increased RNF11 levels would appear to be a beneficial adaptation while other functions of RNF11 suggest that overexpression would be harmful to a cell and lead to accelerated proliferation and cancer development. It appears that RNF11 function is likely too complex to justify a blanket statement of whether RNF11 overexpression is a favorable or unfavorable adaptation. It appears that other factors (i.e. phosphorylation) can influence normal RNF11 function. However, it may be that the upregulation of RNF11 represents a mechanism whereby a cell can cope with some of the alterations in the early stages of cancer development. Much work is necessary to establish the relevance of RNF11 in either preventing or promoting disease progression. However, it does appear that in certain epithelial cancers, RNF11 can play an important role in determining disease severity.
